PMCB (PharmaCyte Biotech) YoY EBITDA Growth: 40.79% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMCB PharmaCyte Biotech Inc PMCB
33 GF Score
Price $0.54
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech YoY EBITDA Growth?

PharmaCyte Biotech PMCB +0.65% 33 YoY EBITDA Growth is 40.79% as of Apr. 2026. GuruFocus rates PMCB with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. PharmaCyte Biotech's YoY EBITDA Growth for the quarter that ended in Apr. 2026 was 40.79%.

PharmaCyte Biotech's EBITDA per Share for the three months ended in Apr. 2026 was $-0.09.

PharmaCyte Biotech YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech YoY EBITDA Growth Chart

PharmaCyte Biotech Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 88.86 -21.25 -105.74 12.33 -6.03

PharmaCyte Biotech Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.57 22.36 -39.31 -65.94 40.79
PMCB
33GF Score
PharmaCyte Biotech Inc PMCB
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

PharmaCyte Biotech's YoY EBITDA Growth for the fiscal year that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (A: Apr. 2026 )
=(EBITDA per Share (A: Apr. 2026 )-EBITDA per Share (A: Apr. 2025 ))/ | EBITDA per Share (A: Apr. 2025 ) |
=(-0.633--0.597)/ | -0.597 |
=-6.03 %

PharmaCyte Biotech's YoY EBITDA Growth for the quarter that ended in Apr. 2026 is calculated as:

YoY EBITDA Growth (Q: Apr. 2026 )
=(EBITDA per Share (Q: Apr. 2026 )-EBITDA per Share (Q: Apr. 2025 )) / | EBITDA per Share (Q: Apr. 2025 )) |
=(-0.09--0.152)/ | -0.152 |
=40.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 40.79% mean?
PharmaCyte Biotech (PMCB) has a YoY EBITDA Growth of 40.79% as of Apr. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's YoY EBITDA Growth too high?
PharmaCyte Biotech's current YoY EBITDA Growth is 40.79%. Overall, PharmaCyte Biotech has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's YoY EBITDA Growth compare to NIKI and IMNN?
PharmaCyte Biotech's YoY EBITDA Growth of 40.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current YoY EBITDA Growth is 40.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current YoY EBITDA Growth of 40.79%. The current YoY EBITDA Growth is 40.79%. PharmaCyte Biotech's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current YoY EBITDA Growth is 40.79% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
33GF Score

Get the complete analysis for PMCB

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price